Overall Survival Benefit Shown for Maintenance Olaparib in Ovarian Cancer

Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

Clinical trial results have shown a 13-month overall survival benefit from maintenance therapy—treatment to prevent or delay recurrence—with olaparib for advanced ovarian cancer.

Go to full article published by The ASCO Post.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.